| First Author | Osaki Y | Year | 2015 |
| Journal | Biochem Biophys Res Commun | Volume | 466 |
| Issue | 3 | Pages | 536-40 |
| PubMed ID | 26381177 | Mgi Jnum | J:232949 |
| Mgi Id | MGI:5780501 | Doi | 10.1016/j.bbrc.2015.09.065 |
| Citation | Osaki Y, et al. (2015) Skeletal muscle-specific HMG-CoA reductase knockout mice exhibit rhabdomyolysis: A model for statin-induced myopathy. Biochem Biophys Res Commun 466(3):536-40 |
| abstractText | HMG-CoA reductase (HMGCR) catalyzes the conversion of HMG-CoA to mevalonic acid (MVA); this is the rate-limiting enzyme of the mevalonate pathway that synthesizes cholesterol. Statins, HMGCR inhibitors, are widely used as cholesterol-reducing drugs. However, statin-induced myopathy is the most adverse side effect of statins. To eludicate the mechanisms underlying statin the myotoxicity and HMGCR function in the skeletal muscle, we developed the skeletal muscle-specific HMGCR knockout mice. Knockout mice exhibited postnatal myopathy with elevated serum creatine kinase levels and necrosis. Myopathy in knockout mice was completely rescued by the oral administration of MVA. These results suggest that skeletal muscle toxicity caused by statins is dependent on the deficiencies of HMGCR enzyme activity and downstream metabolites of the mevalonate pathway in skeletal muscles rather than the liver or other organs. |
